Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-03-15 | AN2 Therapeutics, Inc. | Eckburg Paul
(Chief Medical Officer) |
A | Common Stock | A | 30000 | $0.00 - $0.00 | $0 |
| 2024-03-15 | AN2 Therapeutics, Inc. | Day Lucy
(Chief Financial Officer) |
A | Common Stock | A | 27500 | $0.00 - $0.00 | $0 |
| 2024-03-15 | AN2 Therapeutics, Inc. | Eizen Joshua M
(Chief Legal Officer) |
A | Common Stock | A | 30000 | $0.00 - $0.00 | $0 |
| 2024-03-15 | AN2 Therapeutics, Inc. | Krause Kevin Michael
(Chief Strategy Officer) |
A | Common Stock | A | 30000 | $0.00 - $0.00 | $0 |
| 2024-03-15 | AN2 Therapeutics, Inc. | Chanda Sanjay
(Chief Development Officer) |
A | Common Stock | A | 27500 | $0.00 - $0.00 | $0 |
| 2024-03-15 | AN2 Therapeutics, Inc. | Easom Eric
(Chief Executive Officer) |
A | Common Stock | A | 99000 | $0.00 - $0.00 | $0 |
| 2024-03-15 | AN2 Therapeutics, Inc. | Day Lucy
(Chief Financial Officer) |
A | Common Stock | A | 27500 | $0.00 - $0.00 | $0 |
| 2024-03-15 | AN2 Therapeutics, Inc. | Eizen Joshua M
(Chief Legal Officer) |
A | Common Stock | A | 30000 | $0.00 - $0.00 | $0 |
| 2024-03-15 | AN2 Therapeutics, Inc. | Krause Kevin Michael
(Chief Strategy Officer) |
A | Common Stock | A | 30000 | $0.00 - $0.00 | $0 |
| 2024-03-15 | AN2 Therapeutics, Inc. | Chanda Sanjay
(Chief Development Officer) |
A | Common Stock | A | 27500 | $0.00 - $0.00 | $0 |
| 2024-03-15 | AN2 Therapeutics, Inc. | Eckburg Paul
(Chief Medical Officer) |
A | Common | A | 30000 | $0.00 - $0.00 | $0 |
| 2024-03-15 | AN2 Therapeutics, Inc. | Easom Eric
(Chief Executive Officer) |
A | Common Stock | A | 99000 | $0.00 - $0.00 | $0 |
| 2024-01-18 | AN2 Therapeutics, Inc. | Zakrzewski Joseph S
(Director) |
S | Common Stock | D | 100000 | $19.11 - $19.11 | $1,911,410 |
| 2024-01-16 | AN2 Therapeutics, Inc. | Aziz Kabeer
(Director) |
S | Common Stock | D | 100000 | $19.65 - $19.65 | $1,964,999 |
| 2024-01-16 | AN2 Therapeutics, Inc. | Adjuvant Capital ...
(AtLeastTenPercentOwner) |
S | Common Stock | D | 100000 | $19.65 - $19.65 | $1,964,999 |
| 2024-01-12 | AN2 Therapeutics, Inc. | Readnour Robin Shane
(Director) |
S | Common Stock | D | 1425 | $21.91 - $21.92 | $31,228 |
| 2024-01-10 | AN2 Therapeutics, Inc. | Readnour Robin Shane
(Director) |
S | Common Stock | D | 3669 | $21.92 - $21.93 | $80,443 |
| 2024-01-09 | AN2 Therapeutics, Inc. | Krause Kevin Michael
(Chief Strategy Officer) |
S | Common Stock | D | 7417 | $20.14 - $20.14 | $149,367 |
| 2024-01-09 | AN2 Therapeutics, Inc. | Krause Kevin Michael
(Chief Strategy Officer) |
M | Common Stock | A | 7417 | $0.42 - $6.60 | $34,015 |
| 2024-01-02 | AN2 Therapeutics, Inc. | Krause Kevin Michael
(Chief Strategy Officer) |
S | Common Stock | D | 2583 | $20.12 - $20.12 | $51,967 |
| 2024-01-02 | AN2 Therapeutics, Inc. | Krause Kevin Michael
(Chief Strategy Officer) |
M | Common Stock | A | 2583 | $0.42 - $0.42 | $1,084 |
| 2023-11-14 | AN2 Therapeutics, Inc. | Adjuvant Capital ...
(AtLeastTenPercentOwner) |
S | Common Stock | D | 1810 | $16.15 - $16.15 | $29,224 |
| 2023-11-14 | AN2 Therapeutics, Inc. | Aziz Kabeer
(Director) |
S | Common Stock | D | 1810 | $16.15 - $16.15 | $29,224 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |